

Characterization of 3-aminobiphenyl and 4-aminobiphenyl hemoglobin adducts in adult smokers phenotyped for CYP1A2 and NAT2 activity

Mohamadi Sarkar¹, Roger Walk¹, Regina Stabbert², Robin Kinser¹, and Hans Roethig¹

¹ Philip Morris USA, Worldwide Scientific Affairs, Richmond, VA
² Philip Morris Research Laboratories GmbH, Cologne, Germany

INTRODUCTION

- Human exposure to aromatic amines can occur from various sources including dietary, environmental exposure and tobacco smoke inhalation [1-3].
- Aminobiphenyl (ABP) is one of the aromatic amines that arises from cigarette smoke. Of the various ABPs, 4-ABP is classified by IARC as a bladder carcinogen and human exposure occurs from cigarette smoke as well as other sources; 3-ABP on the other hand is not a carcinogen and is found mainly in cigarette smoke.
- Hepatic N-hydroxylation by the cytochrome P450 enzyme, CYP1A2, is the critical step in the metabolic activation of 4-ABP [6, 7]. Conjugation by N-acetyltransferase (NAT) and glucuronidation competes with N-hydroxylation leading to detoxification [8,9]. The N-hydroxyamine in blood is hemoglobin-mediated oxidized to the nitrosoamine, which reacts with the sulfhydryl group of cysteine in hemoglobin (Hb), resulting in a stable Hb adduct.
- The biologically effective dose of the ultimate carcinogen depends on the rate of formation of the N-hydroxyamine, which is mainly influenced by the balance between N-acetylation and N-hydroxylation of the parent amine. Due to the presence of allelic variants of NAT1 and NAT2 and the induction of CYP1A2 in smokers, this balance can be perturbed in some individuals. Studies have shown a correlation between Hb adduct formation and DNA adduct levels, suggesting that ABP Hb adducts could provide a measure of the biologically effective dose.



- To determine the CYP1A2 and NAT2 phenotypes on 3-ABP and 4-ABP metabolism, (Hb) adduct levels.
- To determine the intra- and inter-individual variability of 3-ABP and 4-ABP Hb adduct levels.

METHODS

Study Population

This was a single center, non-confined, parallel group study design. The study was conducted at Covance Clinical Laboratories, Madison, Wisconsin under a protocol approved by the IRB. The subject population consisted of 136 healthy adults of 21 years or older (smokers (n=88, 30 males and 58 females) and non-smokers (n=48, 32 males and 16 females)).

Sample Collection

Blood samples were obtained from smokers and nonsmokers for Hb adduct determinations on two different occasions separated by 6 weeks. Urine samples were collected for caffeine phenotyping at week 1. Subjects refrained from consuming beverages containing caffeine or alcoholic drinks for a minimum of 8 hrs before and during the day of urine collection. After emptying their urinary bladder, subjects ingested 200 mg of caffeine (No-Doz, 2 tablets at 100 mg each) with 250 ml of water. Consumption of liquids was not restricted during the study. Urine was collected after 4-6 hrs. A 10 ml aliquot of the collected urine (after recording the original volume) was adjusted to pH 3.5 by addition of 200 mg of ascorbic acid, immediately frozen, and stored at -20 °C until analysis.

CYP1A2 and NAT2 Phenotyping

Caffeine and its metabolites were quantified according to the procedure described by Butler et al. [10] with some minor modifications. Caffeine metabolite ratios were used for phenotyping as follows:


$$\text{CYP1A2 activity} = \frac{(1,7\text{-Methylxanthine acid} + 1,7\text{-Methylxanthine})}{1,7\text{-Trimethylxanthine (Caffeine)}}$$

$$\text{NAT2 activity} = \frac{\text{AFMU (5-acetylaminofluoranthene-6-formylamine-3-methylurea)}}{1\text{-Methylxanthine}}$$

Hemoglobin Adduct Measurements

The hemoglobin adducts of 3-aminobiphenyl and 4-aminobiphenyl were measured at Covance Laboratories Limited, Harrogate, England. Briefly, the RBC samples were lysed, centrifuged and supernatant dialyzed over a period of 2-3 days. The concentration of hemoglobin was determined before hydrolysis of the 3-ABP and 4-ABP hemoglobin adducts. Liberated ABPs were then concentrated using solid-phase extraction (C₁₈ reversed phase), eluted with chloroform. After evaporating in dryness, the ABPs were then derivatized with pentafluoropropionic anhydride in hexane, taken to dryness using a vacuum centrifuge and reconstituted in ethyl acetate prior to analysis using capillary GC-MS. The lower limit of quantification (LLOQ) of the method was 0.5 pg/g Hb.

RESULTS



AB Adducts	Smokers			Non-Smokers		
	Female	Male	Total	Female	Male	Total
3-ABP						
Week 1 - N	39	30	69	35	32	67
Mean±SD	0.64±2.3	0.97±4.1	0.85±3.6	0.43±0.8	0.09±0.2	0.18±0.6
Range	0-10.4	0-19.0	0-19.0	0-4.39	0-0.30	0-4.39
Week 6 - N	38	30	68	36	32	68
Mean±SD	0.60±0.97	0.75±0.67	0.72±0.7	0.15±0.43	0.16±0.48	0.15±0.46
Range	0-1.4	0-12.7	0-12.7	0-1.4	0-2.2	0-2.2
4-ABP						
Week 1 - N	39	30	69	35	32	67
Mean±SD	27.30±19.86	40.30±25.5	34.7±19.7	0.14	7.44±6.1	7.24±6.8
Range	0-67.8	10.4-100.6	0-100.6	0-0.14	2.0-26.7	0.6-26.7
Week 6 - N	38	30	68	36	32	68
Mean±SD	3.48±2.61	58.4±21.0	39.2±20.9	8.4±5.86	9.35±5.9	9.09±6.1
Range	0-40.65	0.6-67.8	0-67.8	4.1-23.7	0-10.6	0-40.6



- Results from this study corroborate previous observations.
- The levels of 3-ABP and 4-ABP Hb adducts were significantly higher in smokers compared to nonsmokers.
- Significant correlations were observed between number of cigarettes smoked with the ABP Hb adduct levels indicating cigarette smoke is a major source for ABP in smokers.
- Delectable levels of ABP Hb adducts in nonsmokers suggest that ABP exposure occurs from other sources e.g., dietary, environmental.
- For 53% of the nonsmokers and 6% of the smokers, the 3-ABP Hb adducts were below detectable levels.
- Measurable levels of 4-ABP adducts were observed in both groups.
- 3-ABP Hb adduct levels were about 10-fold lower than 4-ABP Hb adducts in the smokers.
- 4-ABP Hb adduct levels were higher in male smokers compared to female smokers.

- CYP1A2 activity was better correlated with the ABP Hb adducts than NAT2, suggesting that CYP1A2 but not NAT2 plays an important role in ABP metabolism.
- The inter-individual variability was greater for 3-ABP (~30% coefficient of variation, CV) compared to 4-ABP (~52% CV).
- Although there appears to be less confounding factors in the measurement of 3-ABP Hb adducts in nonsmokers, its utility as a biomarker of exposure to cigarette smoke is limited due to the low level observed in smokers.

1. IARC Working Group. Aromatic amines. In: *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals*. Lyon, France: International Agency for Research on Cancer, 1985; 49:1-241.
2. IARC Working Group. Aromatic amines. In: *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals*. Lyon, France: International Agency for Research on Cancer, 1985; 49:1-241.
3. IARC Working Group. Aromatic amines. In: *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals*. Lyon, France: International Agency for Research on Cancer, 1985; 49:1-241.
4. IARC Working Group. Aromatic amines. In: *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals*. Lyon, France: International Agency for Research on Cancer, 1985; 49:1-241.
5. IARC Working Group. Aromatic amines. In: *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals*. Lyon, France: International Agency for Research on Cancer, 1985; 49:1-241.
6. IARC Working Group. Aromatic amines. In: *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals*. Lyon, France: International Agency for Research on Cancer, 1985; 49:1-241.
7. IARC Working Group. Aromatic amines. In: *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals*. Lyon, France: International Agency for Research on Cancer, 1985; 49:1-241.
8. IARC Working Group. Aromatic amines. In: *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals*. Lyon, France: International Agency for Research on Cancer, 1985; 49:1-241.
9. IARC Working Group. Aromatic amines. In: *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals*. Lyon, France: International Agency for Research on Cancer, 1985; 49:1-241.
10. Butler, MA; NP Le; JP Young et al. "Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites." *Pharmacogenetics* 5, 195-197, 1995.